Jogchum Beltman
Biographic Data
| ID | 7784352 |
|---|---|
| NAME | Jogchum Beltman |
| GIVEN NAMES | Jogchum |
| FAMILY NAME | Beltman |
| SIGNATURE | BELTMAN J |
| AFFILIATIONS | Leiden University |
| ORCID | 0000-0002-0048-7360 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2010 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Efficient high-risk human papillomavirus screening through pooled testing
Background: The World Health Organization recommends high-risk human papillomavirus (hrHPV) testing as the primary method for cervical cancer screening. Combining samples in a pool can reduce the expense associated with large numbers of commercially available tests. This study simulated the potential test-saving impact of pooled hrHPV testing using real-world data from two low- and middle-income countries (LMICs). Methods: We simulated a two- and…
The effect of hrHPV prevalence on cervical cancer screening strategies
Our study demonstrates that the hrHPV test + VIA strategy is cost-effective both compared to no screening and VIA + colposcopy screening strategy under the optimal (70%) and realistic (8.7%) uptake scenarios, with greater cost-effectiveness at higher hrHPV prevalence levels. While VIA-based strategy is cheaper, self-sampling hrHPV test-based strategy offers greater health benefits. Implementing hrHPV testing in national screening programs at lowe…
Early evaluation of a screen-and-treat strategy using high-risk HPV testing for Uganda
Background: Uganda has a high burden of cervical cancer and its current coverage of screening based on visual inspection with acetic acid (VIA) is low. High-risk HPV (hrHPV) testing is recommended by the World Health Organization as part of the global elimination strategy for cervical cancer. In this context, country-specific health economic evaluations can inform national-level decisions regarding implementation. We evaluated the recommended hrH…
Investigating feasibility of 2021 WHO protocol for cervical cancer screening in underscreened populations
ClinicalTrials.gov, NCT05234112 . Registered 10 February 2022
Accelerated HIV testing for PMTCT in maternity and labour wards is vital to capture mothers at a critical point in the programme at district level in Malawi
Round the clock (24 hours×7 days) HIV testing is vital to maintain a high prevention of mother to child transmission (PMTCT) coverage for women delivering in district health facilities. PMTCT coverage increases when most of the pregnant women will have their HIV status tested. Therefore routine offering of HIV testing should be integrated and seen as a part of comprehensive antenatal care. For women who miss antenatal care and deliver in a health…
No prominent works on this page.
Accelerated HIV testing for PMTCT in maternity and labour wards is vital to capture mothers at a critical point in the programme at district level in Malawi
Round the clock (24 hours×7 days) HIV testing is vital to maintain a high prevention of mother to child transmission (PMTCT) coverage for women delivering in district health facilities. PMTCT coverage increases when most of the pregnant women will have their HIV status tested. Therefore routine offering of HIV testing should be integrated and seen as a part of comprehensive antenatal care. For women who miss antenatal care and deliver in a health…
Investigating feasibility of 2021 WHO protocol for cervical cancer screening in underscreened populations
ClinicalTrials.gov, NCT05234112 . Registered 10 February 2022
Early evaluation of a screen-and-treat strategy using high-risk HPV testing for Uganda
Background: Uganda has a high burden of cervical cancer and its current coverage of screening based on visual inspection with acetic acid (VIA) is low. High-risk HPV (hrHPV) testing is recommended by the World Health Organization as part of the global elimination strategy for cervical cancer. In this context, country-specific health economic evaluations can inform national-level decisions regarding implementation. We evaluated the recommended hrH…
The effect of hrHPV prevalence on cervical cancer screening strategies
Our study demonstrates that the hrHPV test + VIA strategy is cost-effective both compared to no screening and VIA + colposcopy screening strategy under the optimal (70%) and realistic (8.7%) uptake scenarios, with greater cost-effectiveness at higher hrHPV prevalence levels. While VIA-based strategy is cheaper, self-sampling hrHPV test-based strategy offers greater health benefits. Implementing hrHPV testing in national screening programs at lowe…
Efficient high-risk human papillomavirus screening through pooled testing
Background: The World Health Organization recommends high-risk human papillomavirus (hrHPV) testing as the primary method for cervical cancer screening. Combining samples in a pool can reduce the expense associated with large numbers of commercially available tests. This study simulated the potential test-saving impact of pooled hrHPV testing using real-world data from two low- and middle-income countries (LMICs). Methods: We simulated a two- and…
Cervical Cancer and HPV Research (4 works) · Medicine (4 works) · Cervical cancer (3 works) · Cervical cancer screening (3 works) · Global Cancer Incidence and Screening (3 works) · Biostatistics (2 works) · Cancer (2 works) · Cervical screening (2 works) · Environmental health (2 works) · Family medicine (2 works)